This investigational therapy is currently being evaluated in a modular phase I/II trial for relapsed/refractory MM patients who have received at least three prior lines of therapy, including a PI, an IMiD, and an anti-CD38 antibody. The gene discussed is CD38; the disease is Miyoshi myopathy.